Research & Development 2018-01-05T15:30:47+00:00

Research & Development

Glycadia’s experienced R&D team is bringing new scientific discoveries to clinical trials of innovative products for complications of diabetes, including nephropathy, retinopathy and cardiovascular disease.

Product Pipeline

See the full pipeline for Glycadia’s proprietary new chemical entities.

VIEW

Diabetic Nephropathy

Learn More

Diabetes is the leading cause of kidney failure in the United States...

LEARN MORE

Diabetic Retinopathy

Learn More

Retinopathy affects approximately 30% of patients with diabetes...

LEARN MORE

Diabetic Neuropathy

Learn More

Neuropathy associated with diabetes arises from complex metabolic...

LEARN MORE

Clinical Trials

Learn More

Glycadia has completed Phase Ia and Phase Ib/IIa clinical trials with its lead compound...

LEARN MORE

Diabetic Macrovascular Disease

Learn More

Patients with diabetes are at increased risk for macrovascular complications...

LEARN MORE

Alzheimers Disease

Learn More

Recent experimental work indicates that Glycadia’s compound in clinical development for vascular complications of diabetes may have efficacy in Alzheimer’s disease.

LEARN MORE

New Developments

Recent experimental work indicates that Glycadia’s compound in clinical development for vascular complications of diabetes may have efficacy in Alzheimer’s disease.

LEARN MORE

Clinical Trials

Glycadia has completed Phase Ia and Phase Ib/IIa clinical trials with its lead compound, GLY-230, and is preparing for additional Phase II trials of GLY-230 in patients with diabetes at risk for diabetic nephropathy and diabetic retinopathy.

LEARN MORE